Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib

Authors:

Abstract
Cyclin‑dependent‑kinase 4‑6 inhibitors (CDK4/6i) have improved the management of hormone receptor (HR)+/human epidermal growth factor receptor (HER)2‑ metastatic breast cancer (mBC). Currently, there are no valid prognostic factors for response to CDK4/6i. Baseline lymphopenia is reported as a prognostic factor in several types of cancer. The present retrospective study aimed to evaluate the effect of baseline absolute lymphocyte count (ALC) on response to palbociclib. Progression‑free survival (PFS) was the primary endpoint. Secondary endpoints were overall survival (OS), best response and safety. A total of 114 patients treated for mBC between 2016 and 2019 were included. Median baseline ALC was 1.4 g/l (range, 0.2‑4.3 g/l). A total of 65 (57%) and 49 (43%) patients had baseline ALC values of +/HER2‑ mBC treated with palbociclib and endocrine therapy. Lymphopenia may also be a predictive factor of early progression. These data need to be verified in a larger prospective study.

This publication has 50 references indexed in Scilit: